Search company, investor...



Acquired | Acquired



About Cytiva

Cytiva was one of the first companies to develop an online job board focusing on the tech sector. They also developed SonicRecruit, a web-based solution that automated the entire recruiting process and provided an applicant tracking system. Cytiva also has solutions for onboarding and performance management. In 2011, Cytiva was acquired by Taleo.

Headquarters Location

4089 Emery Street

Emeryville, California, 94608,

United States

Missing: Cytiva's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cytiva's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cytiva

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cytiva is included in 1 Expert Collection, including HR Tech.


HR Tech

4,022 items

HR tech startups are helping companies manage critical pain points in HR processes such as recruitment, automation, career development, compensation, and benefits management, through a mix of software and services.

Cytiva Patents

Cytiva has filed 176 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Chromatography
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics




Proteins, Molecular biology, Clusters of differentiation, Chromatography, Monoclonal antibodies


Application Date


Grant Date



Related Topics

Proteins, Molecular biology, Clusters of differentiation, Chromatography, Monoclonal antibodies



Latest Cytiva News

How to Develop a Scalable AAV Process, from Start to Finish

Jan 13, 2023

Cytiva Scientists Lend Their Insights from Two Years’ Work January 13, 2023   Viral vectors are an integral delivery vehicle in modern medicine and are used in everything from oncolytic viruses to vaccines and gene therapies. With two gene therapies approved by regulatory agencies in 2021 and more in 2022, these therapies are delivering on their promise despite concerns on dosing and safety. Eyes were the first targets; there is growing interest in potential indications for targets in the central nervous system (CNS), liver, and muscles. Of the viral vectors used in gene therapy, adeno-associated virus (AAV) has emerged as the frontrunner In 2021, there were more than 300 gene therapies in clinical trials, about half using AAV. This virus is a versatile tool, with serotypes that target specific tissue types. This fact, combined with the prevalence of engineered variants, creates an almost boundless array of choices. On the flip side of this versatility is the challenge: How do we find ways to produce the various serotypes with high efficiency, sufficient to generate many doses of therapy? Can we learn from monoclonal antibodies (mAbs), which use platform approaches to make grams of material? How do we achieve something similar for AAV? First off, we can’t expect similar outputs for a burgeoning field. With mAbs, it took decades to get such high titers upstream that downstream became a bottleneck. And decades to achieve high recoveries following purification. But what we can do is learn more quickly than we did with mAbs to get better and better. This will take a combination of grit, perseverance, and innovation. AAV is not a mAb. It’s five times larger and is packaged into capsids, which can contain all of the necessary genetic information, partial, or no genetic information. A main challenge upstream is getting a high percentage of full capsids in the harvest. Downstream, it’s effectively separating the full capsids from empties that will reduce efficacy and potentially provoke an immune response. We don’t have all the answers, but we have made progress both upstream and downstream. And we learned a lot of lessons along the way. We believe in the promise of gene therapy, and if you’re reading this you do, too. We hope you find inspiration in the articles in this eBook, so you can bring your own therapy to life. Here we present highlights from a process that has been developed – and continues to be refined – with help from nearly two dozen Cytiva scientists. We frame these highlights around common challenges we hear from those who are developing and producing AAV.

Cytiva Frequently Asked Questions (FAQ)

  • Where is Cytiva's headquarters?

    Cytiva's headquarters is located at 4089 Emery Street, Emeryville.

  • What is Cytiva's latest funding round?

    Cytiva's latest funding round is Acquired.

  • Who are the investors of Cytiva?

    Investors of Cytiva include Taleo.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.